3^{rd}

WORLD BRONCHIECTASIS CONFERENCE



COURSE CHAIR:

Anne E. O'Donnell, MD

MedStar Georgetown University Hospital Georgetown University Medical Center Washington, D.C.

COURSE CO-CHAIR:

Timothy R. Aksamit, MD

Mayo Clinic Rochester, MN JULY 12-14, 2018 GEORGETOWN UNIVERSITY WASHINGTON, D.C.

WorldBronch.com







WELCOME TO THE 3RD WORLD BRONCHIECTASIS CONFERENCE!

On behalf of MedStar Georgetown University Hospital and our prestigious faculty, we are delighted to welcome you to the **3rd World Bronchiectasis Conference 2018 (WBC)**! With over 300 participants from around the world, WBC 2018 will be the most successful program to date! We have created a dynamic agenda and have selected expert faculty in their fields that will provide you with opportunities to expand your network and enhance your knowledge over the next three days.

WBC aims to provide a forum for healthcare professionals, innovators, and researchers to explore the recent advances in the treatment and management of bronchiectasis and NTM. This year, we hope to continue that platform as well as provide an important opportunity for patients and healthcare providers to come together in discussion and interaction during our Saturday afternoon Patient Session.

Over the next few days, we encourage you to network with colleagues and build new relationships. We invite you to examine the material covered and discuss your own approach to patient care. We are confident that the knowledge and expertise shared throughout the conference will be resourceful and yield stronger care in your practice.

We would like to thank all members of our planning committee, abstract committee, faculty, panels, and of course you the attendees. Without your participation, this conference would not continue to grow year over year and provide important educational updates to the healthcare team globally.

Sincerely,



Anne E. O'Donnell, MD
MedStar Georgetown University Hospital
Georgetown University Medical Center
Washington, D.C.



Timothy R. Aksamit, MDMayo Clinic
Rochester, MN

Plan Your WBC 2018 Experience

Table of Contents

Registration Desk Hours	. 4
Exhibit Hall Hours	. 4
Abstract Poster Viewing Hours	4
Meals and Breaks	. 4
Attendee Resources	. 5
Poll Everywhere Instructions	. 5
Faculty	. 6
Agenda	. 8
Abstract Posters	. 11
Acknowledgments	. 16
Note Pages	. 18

KEY

General Information

Registration Desk Hours

Thursday, July 12 Friday, July 13 Saturday, July 14

Exhibit Hall Hours

Thursday, July 12 Friday, July 13 Saturday, July 14

Abstract Poster Viewing Hours

Thursday, July 12 Friday, July 13 Saturday, July 14

MODERATED POSTER VIEWING

Friday, July 13

West Lobby, GUHCC

5:00 p.m. – 8:30 p.m. 7:30 a.m. – 5:00 p.m. 7:30 a.m. – 4:00 p.m.

Salon H. GUHCC

5:00 p.m. – 10:00 p.m. 7:30 a.m. – 6:00 p.m. 7:30 a.m. – 5:00 p.m.

South Gallery, GUHCC

8:30 p.m. – 10:00 p.m. 7:30 a.m. – 6:00 p.m. 7:30 a.m. = 11:45 a.m.

11:45 a.m. – 1:30 p.m. 3:45 p.m. – 5:00 p.m.

Meals and Breaks

Salon H, GUHCC

Thursday, July 12

Opening Reception

Friday, July 13

Breakfast Morning Coffee Break Lunch Afternoon Coffee Break

Saturday, July 14*

Breakfast
Patient Session Coffee Break

8:30 p.m. - 10:00 p.m.

7:30 a.m. - 8:30 a.m. 9:30 a.m. - 9:45 a.m. 11:45 a.m. - 1:30 p.m. 2:30 p.m. - 2:45 p.m.

7:30 a.m. - 8:30 a.m. 2:30 p.m. - 2:45 p.m.

Food and beverage are not permitted in Lohrfink Auditorium.

^{*} Please note that lunch is not provided on Saturday, July 14. The Leavey Center, connected with the Georgetown University Hotel & Conference center, has a Chick-Fil-A and Starbucks that will be open during this time. Epicurian Restaurant, which is a short walk from the hotel, will also be open.

Attendee Resources



HOW TO OBTAIN CE CREDITS AFTER THE CONFERENCE

Within two business days of the conference, you will receive an email containing a link to complete the online evaluation and attest to your CE hours. Once your evaluation has been completed and you select "Submit" you will be able to view and print your CE Certificate and/or MedStar CE Transcript.

Please complete the evaluation by August 14, 2018 in order to access your certificate. You may access your MedStar CE certificates and transcripts anytime at medstar.cloud-cme.com. Please select "My CE", and then "Evaluations & Certificates".

For additional questions regarding CE, please contact medstarcme@gmail.com or 202-780-1655.



PRESENTATIONS

Presentations from the 3rd World Bronchiectasis will be emailed to attendees by July 20.



INTERNET ACCESS

Free Wi-Fi/Internet Access will be available throughout the conference area.

NETWORK: guestnet No passcode required

RESPIRATORY CEU CERTIFICATES

Attendees seeking Respiratory CEUs must visit the registration desk at the start of each day and prior to the Patient Session to record your attendance. Respiratory CEU certificates will be issued on-site at the conference.

Poll Everywhere

Before we begin the program, we will administer a pre-conference survey. You may participate by text message by following the below instructions

- Start a new text message and in the phone number or "to" line, type in 22333.
- Type medstarcme (all one word; not case sensitive) as the message and hit send.
- You will receive a text message saying that you've joined the session.
- When the question appears on the projection screen, the moderator will read each question aloud.
 Simply type your response (A, B, C, D, E, or F) and then hit send.



Course Chair

Course Co-Chair

Anne E. O'Donnell, MD

MedStar Georgetown University Hospital Georgetown University Medical Center Washington, D.C.

Timothy R. Aksamit, MD

Mayo Clinic Rochester, MN

Planning Committee

Doreen J. Addrizzo-Harris, MD

New York University School of Medicine New York, NY

Stefano Aliberti, MD

University of Milan Milan, ITALY

Rupa S. Crite, BS, RRT-NPS

MedStar Georgetown University Hospital Washington, D.C.

Daniel B. Jamieson, MD

Georgetown University Medical Center Washington, D.C.

Won-Jung Koh, MD*

Samsung Medical Center Seoul, SOUTH KOREA

Eric T. Matey, PharmD, RPh, MBA

Mayo Clinic Rochester, MN

Pamela J. McShane, MD*

University of Chicago Chicago, IL

Abstract Committee

Ashwin Basavaraj, MD

New York University School of Medicine New York, NY

Katerina E. Dimakou, MD, PhD

Sotiria General Hospital for Chest Diseases Athens, GREECE

*Faculty is also a member of the Abstract Committee

Felix C. Ringshausen, MD

Hannover Medical School Hanover, GERMANY

Montserrat Vendrell, MD, PhD

Doctor Joseph Trueta University Hospital Girona, SPAIN

Faculty

Josje Altenburg, MD, PhD*

Erasmus Medical Center Amsterdam, THE NETHERI ANDS

Alan F. Barker, MD

Oregon Health and Science University Portland, OR

Peter J. Bergquist, MD

MedStar Georgetown University Hospital Washington, D.C.

James Chalmers, MBChB, PhD

University of Dundee College of Medicine Dundee, UNITED KINGDOM

Charles L. Daley, MD

National Jewish Health Denver, CO

M. Leigh Anne Daniels, MD, MPH*

University of North Carolina Chapel Hill, NC

Anthony De Soyza, MD, PhD*

Newcastle University Newcastle upon Tyne, UNITED KINGDOM

J. Stuart Elborn, MD

Royal Brompton Hospital London, UNITED KINGDOM

Kevin P. Fennelly, MD, MPH

National Institutes of Health Bethesda, MD

Patrick A. Flume, MD

Medical University of South Carolina Charleston, SC

Pieter Goeminne, MD, PhD*

General Hospital Nikolaas Saint-Nicholas, BELGIUM

David E. Griffith, MD

University of Texas Health Science Center Tyler, TX

Charles Haworth, MD

Royal Papworth Hospital Cambridge, UNITED KINGDOM

Gwen A. Huitt, MD

National Jewish Health Denver, CO

Shannon Kasperbauer, MD

National Jewish Health Denver, CO

Marc Margolis, MD

MedStar Georgetown University Hospital Washington, D.C.

Mark L. Metersky, MD

University of Connecticut Farmington, CT

Kozo Morimoto, MD*

Japan Anti-Tuberculosis Association Tokyo, JAPAN

Peadar G. Noone, MD

University of North Carolina Chapel Hill, NC

Kenneth N. Olivier, MD, MPH

National Institutes of Health Bethesda, MD

*Faculty is also a member of the Abstract Committee

Kevin O'Neil, MD, MHA

Wilmington Health Wilmington, NC

Julie V. Philley, MD

University of Texas Health Science Center Tvler, TX

Eva Polverino, MD, PhD*

Hospital Universitari Vall d'Hebron Barcelona, SPAIN

Michal Shteinberg, MD, PhD

Technion-Israel Institute of Technology Haifa, ISRAEL

Gregory Tino, MD

University of Pennsylvania Philadelphia, PA

Kevin Winthrop, MD, MPH

Oregon Health and Science University Hospital Portland, OR

Conroy Wong, MD

Middlemore Hospital Auckland, NEW ZEALAND

THURSDAY JULY 12

Welcome Remarks 7:00 p.m.

> Timothy R. Aksamit, MD: Anne E. O'Donnell, MD

Lohrfink Auditorium, Hariri Building

Opening Address: Current State of 7:15 p.m. **Bronchiectasis and NTM**

> Kevin Winthrop, MD, MPH Lohrfink Auditorium, Hariri Building

Advancing the Understanding 8:00 p.m.

and Care of Patients with

Bronchiectasis

Alan F. Barker, MD

Lohrfink Auditorium, Hariri Building

8:30 p.m. **Opening Reception with**

Exhibitors

Salon H. GUHCC

FRIDAY JULY 13

Breakfast and Visit the Exhibits 7:30 a.m.

Salon H, GUHCC

8:30 a.m. **Breakthrough Therapies for**

Bronchiectasis

Session Chairs: Alan F. Barker, MD; Anthony De Soyza, MD, PhD Speakers: Charles Haworth, MD; Mark L. Metersky, MD

Lohrfink Auditorium, Hariri Building

9:30 a.m. Break and Visit the Exhibits

MORNING 9:45 a.m. **BREAKOUT SESSIONS**

BREAKOUT 1:

How to Evaluate Your Patient

M. Leigh Anne Daniels, MD, MPH

Salon E, GUHCC

BREAKOUT 2:

Implementing a Comprehensive Airway Clearance Program

Pamela J. McShane, MD

Lohrfink Auditorium, Hariri Building

BREAKOUT 3:

Medication Therapy and Pharmacogenetics:

A PharmD's Perspective

Eric T. Matey, PharmD, RPh, MBA

Salon G, GUHCC

10:45 a.m. Microbiology and the Microbiome in

Bronchiectasis and the Impact of Macrolides

Session Chairs: Patrick A. Flume, MD;

Conroy Wong, MD

Speakers: Josie Altenburg, MD, PhD;

J. Stuart Elborn, MD

Lohrfink Auditorium, Hariri Building

11:45 a.m. **Lunch and Moderated Abstract**

Poster Viewing

South Gallery and Salon H, GUHCC

1:30 p.m. Update on Imaging and Diagnosing/ Phenotyping in Bronchiectasis

Session Chairs: Pieter Goeminne, MD, PhD;

Michal Shteinberg, MD, PhD

Speakers: Stefano Aliberti, MD;

Peter J. Bergquist, MD

Lohrfink Auditorium, Hariri Building

Break and Visit the Exhibits 2:30 p.m.

FRIDAY JULY 13 (continued)

2:45 p.m.

AFTFRNOON BREAKOUT SESSIONS

BREAKOUT 1:

How to Evaluate Your Patient

Gregory Tino, MD Ballroom E. GUHCC

BREAKOUT 2:

Implementing a Comprehensive Airway **Clearance Program**

Peadar G. Noone, MD Lohrfink Auditorium, Hariri Building

BREAKOUT 3:

Medication Therapy and Pharmacogenetics: A PharmD's **Perspective**

Eric T. Matey, PharmD, RPh, MBA Salon G, GUHCC

3:45 p.m.

Moderated Abstract Poster Viewing

South Gallery, GUHCC

5:00 p.m.

Inflammation and Infection in Bronchiectatis

Eva Polverino, MD, PhD Speaker: James Chalmers, MBChB, PhD Lohrfink Auditorium, Hariri Building

Session Chairs: Doreen J. Addrizzo-Harris, MD;

SATURDAY JULY 14

NTM SESSION

Lohrfink Auditorium, Hariri Building

Breakfast and Visit the Exhibits 7:30 a.m.

Salon H, GUHCC

8:30 a.m. **Epidemiology and Environmental Factors in NTM**

> Session Chair: Anne E. O'Donnell, MD Speakers: Gwen A. Huitt, MD; Kenneth N. Olivier, MD, MPH

9:30 a.m. **Management of NTM Infections:** Now and the Future

> Session Chairs: David E. Griffith, MD; Kozo Morimoto, MD Speakers: Charles L. Daley, MD; Won-Juna Koh, MD

10:30 a.m.

Panel Discussion: A Spectrum of NTM Cases

Moderators: Kevin P. Fennelly, MD, MPH; David E. Griffith, MD; Won-Jung Koh, MD Panelists: Shannon Kasperbauer, MD: Marc Margolis, MD; Julie V. Philley, MD;

Kevin Winthrop, MD, MPH

Closing Remarks 11:45 a.m.

> Timothy R. Aksamit, MD: Anne E. O'Donnell, MD

Please note that lunch is not provided on Saturday, July 14, 2018. Please see the bottom of page 4 for more details on local lunch options.

SATURDAY JULY 14

PATIENT SESSION

Salon G, GUHCC

Patient Session Registration* I Have Pseudomonas Infection: 12:00 p.m. 3:15 p.m. What Are My Options? West Lobby, GUHCC

Overview of Bronchiectasis and NTM 1:00 p.m.

Pamela J. McShane, MD

Provider Panel Discussion Why Do I Need Airway Clearance 1:30 p.m.

and Pulmonary Rehab?

M. Leigh Anne Daniels, MD, MPH

What Can I Do About My 2:00 p.m.

Environment?

Anne E. O'Donnell, MD

2:30 p.m. Break 4:45 p.m.

I Have an NTM Infection (MAC/M. 2:45 p.m.

Abscessus): What are My Options?

Julie V. Philley, MD

Gregory Tino, MD

Joint Patient/Healthcare 3:45 p.m.

Moderator: Anne E. O'Donnell, MD

Panelists: Christy Heuple; Shannon Kasperbauer, MD; Isabelle LeClerc, RN;

Kenneth N. Olivier, MD, MPH;

Kevin O'Neil, MD, MHA

Closing Remarks

Timothy R. Aksamit, MD; Anne E. O'Donnell, MD

*Those registered for the full three-day conference do not need to visit the registration desk again prior to the Patient Session.



TOP ABSTRACT AWARD

Pregnancy Zone Protein (PZP) is Released from Neutrophils During Chronic Airway Inflammation B-1 in Bronchiectasis

Presenting Author: Simon Finch, MD; Additional Authors: Diane Cassidy; James D. Chalmers, MD, PhD; Holly R. Keir; Amelia Shoemark, PhD

YOUNG INVESTIGATOR AWARD

B-2 Neutrophil Extracellular Traps and the Lung Microbiome in Bronchiectasis

Presenting Author: Holly R. Keir

Additional Authors: James D. Chalmers, MD, PhD; Alison Dicker, PhD; Christopher Fong, MD; Brandon Tan

ABSTRACTS BY CATEGORY

GENERAL BRONCHIECTASIS

Δ-1 Effect of Inhaled Liposomal Ciprofloxacin on Severe Pulmonary Exacerbations in Patients with Bronchiectasis and Chronic Pseudomonas Aeruginosa **Luna Infections**

> James Chalmers, MBChB, PhD; Angela Davis, MD; Juergen Froehlich, MD; Igor Gonda, MD; Charles Haworth, MD; Anne E. O'Donnell, MD

A-2 The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency, and Primary Ciliary Dyskinesia

> Doreen J. Addrizzo-Harris, MD; Timothy R. Aksamit, MD; Alan F. Barker, MD; Radmila Choate, MPH; Charles L. Daley, MD; M. Leigh Anne Daniels, MD, MPH; Angela DiMango; Edward Eden; Kevin Fennelly, MD, MPH; David E. Griffith, MD; Margaret Johnson; Michael Knowles; Mark L. Metersky, MD; Peadar G. Noone, MD; Anne E. O'Donnell, MD; Kenneth Olivier, MD, MPH; Matthias Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino, MD; Kevin Winthrop, MD, MPH

Pulmonary Rehabilitation in Bronchiectasis - Program Components, Outcomes A-3 and Insurance Billing Codes

Shane S. Blake; Gerilynn A. Connors, BS; James Lamberti, MD; Kimberly Palczynski

- The Comparison of Bronchiectatic Lung Disease in Different Ages **A-4** Adi Dagan, MD; Ori Efrati, MD; Amir Onn, MD
- **A-5** A Passport for Patients with Non-Cystic Fibrosis Bronchiectasis: A Qualitative Investigation of Patients' Beliefs and Expectations Anthony De Soyza, MD, PhD; Paul McCallion, PT
- A Pilot Study of Vitamin D3 Supplementation in Adults with Non-CF Bronchiectasis A-6 Jim Bartley; Benjamin A. Diggins; Jeff Garrett; Alain Vandal, OTR; Conroy Wong, MD

A-7	Longitudinal Analysis of Pulmonary Exacerbations: Results from Orbit-3 and Orbit-4 Trials of
	Ard-3150 in Patients with Non-Cystic Fibrosis Bronchiectasis and Chronic Infection With
	Pseudomonas Aeruginosa
	David Cinolla, MD: Angela Davis, MD: Juergen Froehlich, MD: Jgor Gonda, MD: Bruce Thompson, MD

- **A-8** Safety and Tolerability of Ard-3150, Inhaled Liposomal Ciprofloxacin, in Patients with Bronchiectasis and Chronic Pseudomonas Aeruginosa Lung Infection: Results from Two Phase 3 Trials Angela Davis, MD; Juergen Froehlich, MD; Igor Gonda, MD; Charles Haworth, MD; Anne E. O'Donnell, MD; Sanjay Sethi, MD
- **A-9** Comparative Risks of Non-Acute Inhaled Corticosteroids or Macrolide Monotherapy in U.S. Medicare **Bronchiectasis Patients** Emily Henkle, PhD; Alexandra L. Quittner, PhD; Greg Ranches, MD; Kevin L. Winthrop, MD, MPH
- A-10 Clinical, Functional and Microbiologic Characteristics of Patients with Co-Existence COPD And Bronchiectasis: Comparison to COPD or Bronchiectasis Alone Katerina Dimakou, MD, PhD; Georgios Drivas, MD; Georgios Hillas, MD, PhD; Maria Kaponi, MD, MBA;
- Sofia Koukidou, MD
- A-11 The Clinical Impact of Self-Reported Symptoms of Chronic Rhinosinusitis in Adults with Bronchiectasis Janet L. Bondarenko, PT; Brenda M. Button, PhD; Annemarie L. Lee, PhD; Caroline H. Nicolson
- Δ-12 Parental Perception of Quality of Life in Children with Bronchiectasis Narelle S. Cox, PhD; Anne B. Chang, PhD; Annemarie L. Lee, PhD
- Inhaled Steroids Improve Quality of Life Only in Those Patients with Bronchiectasis and Peripheral A-13 Eosinophilia: A Post-Hoc Analysis of a Randomized Clinical Trial Stefano Aliberti, MD, PhD; David de La Rosa, MD, PhD; Luis Maiz, MD, PhD; Miguel Angel Martinez-Garcia, MD, PhD; Casilda Olveira, MD, PhD
- "Idiopathic" Bronchiectasis in an Older Patient: Use of Standard Clinical Methods, with Novel Δ-14 Laboratory Techniques to Establish a Specific Diagnosis Deborah M. Cholon, PhD; Martina S. Gentzsch, PhD; Matthew S. McCravy, MD; Peadar G. Noone, MD; Nancy L. Quinney
- A-15 Age, Fev1 and Severe Exacerbation Frequency are Major Determinants of Impaired Quality of Life (QOL) for Australians with Bronchiectasis

Anne Chang, MD, PhD; Cameron Hunter, MD; Graeme Maguire, MD, PhD; Peter Middleton, MD, PhD; Dean Mills, PhD; Lucy Morgan, MD, PhD; Enna Stroil-Salama; Rachel Thomson, MD PhD; Simone Visser, MD; Grant Waterer, MD, PhD

A-16 Independent Predictors of Primary Ciliary Dyskinesia as the Etiology of Adult Bronchiectasis: Results from the German Bronchiectasis Registry Prognosis Roland Diel; Pontus Mertsch, MD; Jessica Rademacher, MD; Felix C. Ringshausen, MD; Tobias Welte, MD

- A-17 Primary Ciliary Dyskinesia in Adults with Bronchiectasis: Data from the Embarc Registry Stefano Alberti, MD; F. Blasi; W. Boersma; James Chalmers, MBChB, PhD; Anthony De Soyza, MD, PhD; Katerina Dimakou, MD, J. Stuart Elborn, MD; PhD; Pieter Goeminne, MD, PhD; Charles Haworth, MD; Adam T. Hill; Michael Loebinger, MD; Rosario Menéndez; M. Murris; Eva Polverino, MD, PHD; Felix C. Ringshausen, MD; Amelia Shoemark, PhD; A. Torres; Montserrat Vendrell, MD, PhD; T. Welte; R. Wilson.
- A-18 A Randomized Controlled Trial of Long Term Airway Clearance with Oscillating Positive End Expiratory Pressure Device Versus Autogenic Drainage in People with Bronchiectasis - 30 Patients **Interim Analysis** Yochai Adir, MD, MPH; Lea Bentur, MD; Galit Livnat, MD; Michal Shteinberg, MD, PhD; Naama Yaari, BSN
- High Frequency Chest Wall Oscillation Physiotherapy as Part of a Bundle of Care Results in Reduced A-19

Hospitalizations and Stability of Lung Function in Non-CF Bronchiectasis

Powner M. Jordan, DO; Denay P. Kirkpatrick, CRNP; Andrew B. Nesmith; Jessica K. Nichols, BSN; George M. Solomon, MD

MARKERS, MECHANISMS, AND MICROBIOLOGY

- **B-3** Comparison Between Culture and Culture Independent Assessment of Bronchoalveolar Lavage Fluid in Bronchiectasis
 - Doreen Addrizzo-Harris, MD; Shriram V. Alapaty, MD; Leopoldo Segal, MD; Imran Suleiman, MD; Benjamin Wu, MD
- Bronchiectasis and Fungal Sensitization A Marker of Disease Severity But Not Exacerbation Risk **B-4** Stefano Alberti, MD; F. Blasi; Rita Boaventura, MD; W. Boersma; James Chalmers, MBChB, PhD; Anthony De Soyza, MD, PhD; Katerina Dimakou, MD, PHD; J. Stuart Elborn, MD; Pieter Goeminne, MD, PHD; Charles Haworth, MD; Adam T. Hill; Michael R. Loebinger, MD; Rosario Menéndez; M. Murris; Eva Polverino, MD, PhD; P. Regis-Burgel; Felix C. Ringshausen, MD; A. Torres; Montserrat Vendrell, MD, PhD; T. Welte; R. Wilson
- Markers of Non-Cystic Fibrosis Bronchiectasis Disease Severity and Nutrition in the United States **B-5 Bronchiectasis Research Registry**

Radmila Choate, MPH; M. Leigh Anne Daniels, MD, MPH; Katherine Despotes, MD; Peadar G. Noone, MD

B-6 Aspergillus Airway Colonization in Non-CF Bronchiectasis Patients is Not Associated with **Disease Severity**

Doreen Addrizzo-Harris; Timothy R. Aksamit, MD; Alan Barker, MD; Charles L. Daley, MD; M. Leigh Anne Daniels, MD, MPH; Edward Eden, MD; Radmila Choate, MPH; Angela DiMango, MD; Kevin Fennelly, MD; David E. Griffith, MD; Margaret M. Johnson, MD; Michael R. Knowles, MD; David Mannino, MD; Mark L. Metersky, MD; Peadar G. Noone, MD; Anne E. O'Donnell, MD; Kenneth N. Olivier, MD, MPH; Matthias A. Salathe, MD; Andreas Schmid, MD; Byron Thomashow, MD; Gregory Tino, MD; Kevin L. Winthrop, MD, MPH

- Microbial Spectrum of Sputum in Patients with Bronchiectasis in Stable Phase **B-7** Kateryna Bogatska, MD; Valeriia Dmytrychenko, MD; Kateryna Gahynova, MD, PhD; Tetyana Kireyeva, MD; Tetyana Pertseva, MD, PhD
- **B-8** Histopathologic Manifestations of Idiopathic Bronchiectasis in an Endobronchial Biopsy Based Series Sarah E. Gray, MD; Kyle D. Hogarth, MD; Aliya N. Husain, MD; Pamela J. McShane, MD

B-9 The Association of Stenotrophomonas Maltophilia with Patient Characteristics and Outcomes in Bronchiectasis

Radmila Choate, MPH; Mark Metersky, MD

B-10 Potent Activity of a Novel Gyrase Inhibitor (Spr719/Spr720) In Vitro and in a Prolonged Acute Mycobacterium Abscessus Mouse Model of Infection

Diane Ordway, PhD; Aileen Rubio, PhD

B-11 Autoimmunity to Bactericidal/Permeability-Increasing Protein in Chronic Airway Infection of **Bronchiectasis and Cystic Fibrosis Patients**

Sladjana S. Gardner, PhD; Rachel E. Meagher; William F. Rigby, MD; Jomkuan Theprungsirikul, BS; Kevin L. Winthrop, MD, PhD

NTM

C-1 Cinical Significance of Serum Anti-Glycopeptidolipid-Core Iga Antibody in Patients Newly Diagnosed with Mycobacterium Avium Complex Lung Disease

Takanori Asakura, MD, PhD; Hajime Goto, MD, PhD; Naoki Hasegawa, MD, PhD; Shuichi Matsuda, MD; Kozo Morimoto, MD, PhD

C-2 High-Dose Inhaled Nitric Oxide as a Potential Therapy Against Mycobacterium Abscessus Lung Infection in Cystic Fibrosis

Kristijan Boqdanovski; Abdi A. Ghaffari, PhD; Joas L. da Silva, Kenneth Olivier, MD, MPH, PhD; Adrian M. Zelazny, PhD

- C-3 Health-Related Quality of Life in Bronchiectasis Patients with Nontuberculous Mycobacterial Disease Kieren C. Brown, MBBS; Lucy Burr, MD; Lucy C. Morgan, MD, PhD; Enna Stroil-Salama; Rachel Thomson, MD, PhD
- C-4 Colonization with Pseudomonas Aeruginosa as a Predictor of Future Nontuberculous Mycobacteria Isolation

Timothy R. Aksamit, MD; Amanda E. Brunton, MPH; Sarah A. Siegel, MPH; Kevin L. Winthrop, MD, MPH

- **C-5 Antimicrobial Peptides Against Mycobacterium Abscessus** Joas DaSilva, PhD; Kevin P. Fennelly, MD; Kenneth N. Olivier, MD, MPH; Adrian M. Zelazny, PhD
- **C-6** Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial Lung Disease Caused By Mycobacterium Avium Complex (MAC-LD) in Adult Patients

Doreen J. Addrizzo-Harris, MD; Timothy R. Aksamit, MD; Paola F. Castellotti, MD; Gina Eagle, MD; Stephen K. Field, MD; Patrick A. Flume, MD; David E. Griffith, MD; Naoki Hasegawa; Adam T. Hill; Michael R. Loebinger, MD; Theodore K. Marras, MD; Lucy C. Morgan, MD, PhD; Kozo Morimoto, MD; Jim P. Nezamis, PhD; Anne E. O'Donnell, MD; Felix C. Ringshausen, MD; Stephen J. Ruoss, MD; Rachel M. Thomson, MD, PhD; Kevin L. Winthrop, MD; Jae Joon Yim, MD

C-7 Psychometric Analyses of the NTM Module: First Patient-Reported Reported Outcome Measure for Pulmonary Nontuberculous Mycobacterial Disease

Emily Henkle, PhD; Alexandra L. Quittner, PhD; Greg Ranches, MD; Kevin L. Winthrop, MD, MPH

C-0	Jennifer Ku, MPH; Gregory Ranches, MD; Sarah A. Siegel, MPH; Kevin L. Winthrop, MD, MPH
C-9	Long-Term Natural History of Non-Cavitary Nodular Bronchiectatic Nontuberculous Mycobacterial

dy Windormoro's Dudomoro? Dulmonary NTM in Mon

Lung Disease

Charles L. Daley, MD; Kyeongman Jeon, MD; Byung Woo Jhun, MD; Won-Jung Koh, MD; Seong Mi Moon, MD

- C-10 Treatment of Refractory Mycobacterium Abscessus Lung Infection with Inhaled Intermittent Nitric Oxide Sandra D. Macdonald, RN; Kenneth N. Olivier, MD, MPH; Ann M. Peterson, PhD; Mark V. Rimkus, RT; Chevalia J. Robinson, RN
- Vitamin D Deficiency Increases the Risk of Pulmonary Nontuberculous Mycobacteria in Cystic Fibrosis C-11 Keira A. Cohen, MD; Mark T. Jennings, MD; Matthew N. Santos; Aniket Sidhaye, MD; Yuqing Sun, PhD
- C-12 Perception for Risk and Disease Severity of NTM Lung Disease - Physician Survey in Germany, UK, Italy, France and The Netherlands Marko Obradovic, PhD; Roald van der Laan, PhD; Jakko van Ingen, MD, PhD; Dirk Wagner, MD, PhD
- C-13 Screening for NTM Lung Disease in Adult Non-CF Bronchiectasis Patients - Physician Survey in Germany, UK, Italy, France and The Netherlands Marko Obradovic, PhD; Roald van der Laan, PhD; Jakko van Ingen, MD, PhD; Dirk Wagner, MD, PhD
- Six-Minute Walk Test (6MWT) Performance in Adult Patients Receiving Amikacin Liposome C-14 Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) Doreen J. Addrizzo-Harris, MD; Timothy R. Aksamit, MD; Luigi R. Codecasa, MD; Gina Eagle, MD; Stephen K. Field, MD; Patrick A. Flume, MD; David E. Griffith, MD; Naoki Hasegawa; Adam T. Hill; Michael R. Loebinger, MD; Theodore K. Marras, MD; Lucy C. Morgan, MD, PhD; Kozo Morimoto, MD; Jim P. Nezamis, PhD; Anne E. O'Donnell, MD; Felix C. Ringshausen, MD; Stephen J. Ruoss, MD; Rachel M. Thomson, MD, PhD; Kevin L. Winthrop, MD; Jae Joon Yim, MD
- C-15 Rate of All-Cause Hospitalization Between Treatment Groups Following Diagnosis of Nontuberculous Mycobacterial Lung Disease in a US National Managed Care Plan Engels Chou, MS; Gina Eagle, MD; Theodore Marras, MD; Mehdi Mirsaeidi, MD, MPH; Ping Wang, PhD; Raymond Zhang, MS; Quanwu Zhang, PhD

MedStar Georgetown University Hospital would like to acknowledge the generous educational grant from:

Richard H. Scarborough Bronchiectasis Fund

Acknowledgements

MedStar Georgetown University Hospital would like to acknowledge the following exhibitors:

GOLD

Insmed, Inc.

SILVER

Grifols

BRONZE

AIT Therapeutics Electromed, Inc. **International Biophysics Corporation** RespirTech

NOTES:	

NOTES:	

NOTES:	

NOTES:	

NOTES:	

NOTES:	

NOTES:	

NOTES:	

NOTES:	



What could be worse than having NTM? **Not knowing you have NTM.**

Nontuberculous mycobacterial (NTM) lung disease is a chronic, debilitating condition that can significantly increase patient **morbidity and mortality**¹⁻⁵

- Approximately **2/3 of NTM patients** have moderate to severe NTM by the time they are diagnosed^{6,7}
- Host susceptibility factors that increase risk for NTM include bronchiectasis, COPD, asthma, and other conditions or specific genetic disorders that cause structural lung damage and impaired clearance⁸⁻¹⁰
 - Patients with susceptibility factors, such as these underlying conditions, who present with pulmonary (eg, chronic cough) and nonspecific systemic symptoms (eg, malaise or fever) should be assessed for NTM^{9,11}

Visit **NTMFacts.com** for more information.

References: 1. Griffith DE, Aksamit T, Brown-Elliott BA, et al; for the ATS Mycobacterial Diseases Subcommittee. Am J Respir Crit Care Med. 2007;175(4):367-416. 2. Winthrop KL, McNelley E, Kendall B, et al. Am J Respir Crit Care Med. 2010;182(7):977-982. 3. Park HY, Jeong B-H, Chon HA, Jeon K, Daley CL, Koh W-J. Chest. 2016;150(6):1222-1232. 4. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots D Re. Am J Respir Crit Care Med. 2012;185(8):881-886. 5. Fleshner M, Olivier KN, Seitz AE, Holland SM, Prevots D R. Am J Respir Crit Care Med. 2012;185(8):881-886. 5. Fleshner M, Olivier KN, Seitz AE, Holland SM, Prevots D R. Am J Respir Crit Care Med. 2012;185(8):881-886. 5. Fleshner M, Olivier KN, Shaw PA, et al. Th. J Tuber C Lung Dis. 2016;20(5):582-587. 6. Wagner D, van Ingen J, Adjemian J, et al. Poster presented at: European Respiratory Society (ERS) Annual Congress, September 6-10, 2014; Munich, Germany. 7. Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Järvinen A. Eur J Clin Microbiol Infect Dis. 2015;34(9):1909-1918. 8. Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Thorax. 2013;68(3):256-262. 9. Fritscher LG, Marras TK, Bracil AC, Fritscher CC, Balter MS, Chapman KR. Chest. 2011;139(1):23-27. 10. Szymanski EP, Leung JM, Fowler CJ, et al. Am J Respir Crit Care Med. 2015;192(5):618-628. 11. Young JD, Balagopal A, Reddy NS, Schlesinger LS. J Respir Dis. 2007;28(1):7-18.



